Disc medicine CFO Franchi sells $119k in shares

Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (NASDAQ:IRON), sold 2,031 shares of common stock on July 17, 2025, at a price of $59.00, totaling $119,829. The transaction occurred near the stock’s current trading price of $57.77, with the company maintaining a market capitalization of $2 billion. According to InvestingPro analysis, IRON has shown strong price momentum despite its characteristic volatility.

Following the transaction, Franchi directly owns 63,499 shares of Disc Medicine. The sale was executed under a Rule 10b5-1 trading plan adopted on March 10, 2025. While the stock has delivered a robust 25% return over the past year, InvestingPro subscribers can access 12 additional key insights about IRON’s financial health and growth prospects through the comprehensive Pro Research Report.

In other recent news, Disc Medicine has been in the spotlight with several significant developments. Morgan Stanley (NYSE:MS) initiated coverage on Disc Medicine with an Overweight rating and set a price target of $85.00, citing bitopertin’s potential for accelerated market approval. This comes as H.C. Wainwright reaffirmed its Buy rating on the company with a price target of $118.00, highlighting progress with bitopertin for Erythropoietic Protoporphyria (EPP) and the potential of DISC-0974 in treating myelofibrosis. Meanwhile, Raymond (NSE:RYMD) James reiterated a Strong Buy rating, maintaining an $89.00 price target, following Bristol Myers (NYSE:BMY) Squibb’s trial results for luspatercept. Additionally, Disc Medicine announced the appointment of Nadim Ahmed to its board of directors. Ahmed brings extensive leadership experience from his previous roles at Cullinan Therapeutics and Bristol Myers Squibb. These developments indicate ongoing strategic moves and potential advancements in Disc Medicine’s pipeline programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.